Journal retracts paper on MI risk with e-cigarette use, gut microbial metabolite tied to CHD — top stories in cardiology
Click Here to Manage Email Alerts
The Journal of the American Heart Association retracted a study that concluded patients who actively smoked electronic cigarettes had an increased risk for MI. It was the top story in cardiology last week.
Another top story was about study that showed healthy women with long-term changes in plasma trimethylamine N-oxide had an increased risk for coronary heart disease (CHD).
Read these and more news in cardiology below:
Paper on e-cigarette use and MI risk retracted
A study published in the Journal of the American Heart Association in June 2019 concluding that patients who smoked electronic cigarettes every day or some days had an increased risk for MI was retracted on Feb. 18, 2020. Read more.
Rise in gut microbial metabolite may elevate CHD risk
Healthy women with long-term changes in plasma trimethylamine N-oxide, a choline metabolite produced from gut microbiota, had an increased risk for CHD, which may be modified by healthy dietary patterns, according to a prospective nested case-control study published in the Journal of the American College of Cardiology. Read more.
Sitting longer increases risk for cardiometabolic disorders in women
Sitting for longer periods of time conferred worse parameters of cardiovascular disease (CVD) risk in women, but the effect on blood sugar/glucose was most pronounced in Hispanic women, according to a study published in a Go Red for Women-focused issue of the Journal of the American Heart Association. Read more.
AHA: Improvements in rural health greatly needed
The American Heart Association issued a presidential advisory calling for rural populations to be a priority in health research, programming and policy. Read more.
FDA approves bempedoic acid for LDL lowering in high-risk populations
The FDA has approved bempedoic acid for reducing LDL as an adjunct to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia or established atherosclerotic CVD, according to the agency’s website and an alert from Esperion Therapeutics. Read more.